Within the framework of the project titled "National Cardiovascular Laboratory" with identification number RRF-2.3.1-21-2022-00003, a framework agreement for the purchase of reagents and antibodies for Semmelweis University, Institute of Genetics, Cell, and Immunobiology will be concluded until the framework amount of net HUF 41,107,005 is exhausted. The subject of the public procurement procedure consists of the purchase of a total of 107 items in 9 lots. It is mandatory to submit a bid for all items in each lot. If all items are not proposed, the bidder's bid will be invalid for that lot. The quantities affected by the call-off will be determined by the amounts available in the framework for each lot specified below. Lot 1: Heterogeneous marker antibodies (10 items), framework amount: net HUF 2,444,172. Lot 2: Antibodies for immunophenotyping and apoptosis testing (11 items), framework amount: net HUF 1,651,074. Lot 3: Exosome and activation marker antibodies (8 items), framework amount: net HUF 2,922,194. Lot 4: Antibodies needed for general protein work (20 items), framework amount: net HUF 2,767,506. Lot 5: Simple reagents necessary for general protein work (15 items), framework amount: net HUF 2,732,896. Lot 6: Antibodies used for flow cytometry and Western blot (7 items), framework amount: net HUF 1,323,442. Lot 7: Specific kits used with leprechaun-type measuring devices (8 items), framework amount: net HUF 16,957,570. Lot 8: Specific kits used with Quanterix-type measuring devices (17 items), framework amount: net HUF 9,263,436. Lot 9: Antibodies needed for stem cell work (11 items), framework amount: net HUF 1,044,715. This procedure aims to conclude a framework agreement with one bidder per lot in accordance with the provisions of Section 105(1)(a) of the Public Procurement Act. Individual orders will be placed by direct order. The successful bidders must undertake to deliver the products within 40 days of the order. Detailed rules for call-offs are contained in the framework agreement. A detailed description of the subject of procurement, as well as the planned quantities for each item, is included in the itemized price list made available as part of the public procurement documents. If the technical description refers to a specific manufacturer, origin, type of item, activity, patent, or trademark, it is only for the clear identification of the subject matter; equivalent offers will be accepted by the contracting authority. The equivalence must be verified by the bidder in their offer. The contracting authority will evaluate the bids based on the criteria of the lowest price, taking into account the specific rules on procurement of medicines and medical devices specified in Section 6(3) of Government Decree 16/2012. The contracting authority does not require and does not allow the successful bidder(s) to establish an economic organization (project company) for the performance of the contract.
LOT-0001
EKR000658412025/1
Heterogeneous marker antibodies.
Lot 1: Heterogeneous marker antibodies (10 items), framework amount: net HUF 2,444,172. AnnexinV-AF647 anti-mo CD206-BV650 anti-mo CD326-APC anti-mo CD3-FITC anti-mo CD3-PE anti-mo/rat CD81-PerCP/Cy5.5 anti-mouse CD16, APC anti-mouse CD309, PerCP/Cyanine5.5 anti-mouse CD31, Pacific Blue APC anti-mouse CD16 Antibody Planned quantity: 1,700 units. The detailed description of the subject of procurement, as well as the planned quantities, is included in the itemized price list provided as part of the public procurement documents. The contracting authority evaluates the offers based on the criterion of the lowest price, considering the specific rules for the procurement of medicines and medical devices specified in Section 6(3) of Government Decree 16/2012. Main financing conditions: The contracting authority will pay the value of the verified delivered call-offs later, within 30 days of receiving the invoice, via bank transfer, in accordance with Sections 135(1), (5)-(6) and (10) of the Public Procurement Act, considering the provisions of Section 6:130(1)-(2) of the Civil Code. Form of financing: post-financing. Support intensity: 100%. In case of delayed payment by the client, the Contractor is entitled to claim late interest in accordance with Section 6:155 of the Civil Code and the claim for arrears debt recovery as per Section 3 of the Act IX of 2016 on the Collection Costs. Payment currency: HUF. The contracting authority draws the bidders' attention to the provisions of Section 136(1) of the Public Procurement Act regarding payments and the special termination reason stated in Section 143(3). The detailed conditions for financial performance and financing are included in the draft contract.
LOT-0002
EKR000658412025/2
Antibodies for immunophenotyping and apoptosis testing.
Lot 2: Antibodies for immunophenotyping and apoptosis testing (11 items), framework amount: net HUF 1,651,074. AnnexinV-FITC AnnexinV-PE anti-hu/mo CD11b-PE anti-mo CD11c-FITC anti-mo CD11c-PE/Cy7 anti-mo CD172a-AF647 anti-mo CD19-PE/Cy7 anti-mo CD45.1-PerCP/Cy5.5 anti-mo CD45-AF647 anti-mo CD4-AF647 anti-mo CD4-PerCP/Cy5.5 Planned quantity: 1,600 units. The detailed description of the subject of procurement, as well as the planned quantities, is included in the itemized price list provided as part of the public procurement documents. The contracting authority evaluates the offers based on the criterion of the lowest price, considering the specific rules for the procurement of medicines and medical devices specified in Section 6(3) of Government Decree 16/2012. Main financing conditions: The contracting authority will pay the value of the verified delivered call-offs later, within 30 days of receiving the invoice, via bank transfer, in accordance with Sections 135(1), (5)-(6) and (10) of the Public Procurement Act, considering the provisions of Section 6:130(1)-(2) of the Civil Code. Form of financing: post-financing. Support intensity: 100%. In case of delayed payment by the client, the Contractor is entitled to claim late interest in accordance with Section 6:155 of the Civil Code and the claim for arrears debt recovery as per Section 3 of the Act IX of 2016 on the Collection Costs. Payment currency: HUF. The contracting authority draws the bidders' attention to the provisions of Section 136(1) of the Public Procurement Act regarding payments and the special termination reason stated in Section 143(3). The detailed conditions for financial performance and financing are included in the draft contract.
LOT-0003
EKR000658412025/3
Exosome and activation marker antibodies.
Lot 3: Exosome and activation marker antibodies (8 items), framework amount: net HUF 2,922,194. anti-mo CD63-APC anti-mo CD63-PerCP/Cy5.5 anti-mo CD8a-APC/Cy7 anti-mo CD9-APC anti-mo CD9-PerCP/Cyanine5.5 anti-mo F4/80-PE anti-mo FcεRIα-FITC Annexin V binding buffer Planned quantity: 1,825 units. The detailed description of the subject of procurement, as well as the planned quantities, is included in the itemized price list provided as part of the public procurement documents. The contracting authority evaluates the offers based on the criterion of the lowest price, considering the specific rules for the procurement of medicines and medical devices specified in Section 6(3) of Government Decree 16/2012. Main financing conditions: The contracting authority will pay the value of the verified delivered call-offs later, within 30 days of receiving the invoice, via bank transfer, in accordance with Sections 135(1), (5)-(6) and (10) of the Public Procurement Act, considering the provisions of Section 6:130(1)-(2) of the Civil Code. Form of financing: post-financing. Support intensity: 100%. In case of delayed payment by the client, the Contractor is entitled to claim late interest in accordance with Section 6:155 of the Civil Code and the claim for arrears debt recovery as per Section 3 of the Act IX of 2016 on the Collection Costs. Payment currency: HUF. The contracting authority draws the bidders' attention to the provisions of Section 136(1) of the Public Procurement Act regarding payments and the special termination reason stated in Section 143(3). The detailed conditions for financial performance and financing are included in the draft contract.
LOT-0005
EKR000658412025/5
Simple reagents necessary for general protein work.
Lot 5: Simple reagents necessary for general protein work (15 items), framework amount: net HUF 2,732,896. LDL (human) Ox-LDL (human) HEPES, 1M Buffer Solution CD ITS Mouse T-Activator CD3/CD28 for T-Cell Expansion and Activation Histopaque-1083 mouse TNFa sandwich ELISA kit mouse IFNg sandwich ELISA kit mouse IL-1b sandwich ELISA kit mouse IL1 beta ELISA mouse TNF alpha ELISA Claycomb medium (500ml) hygromycin mitomycin Planned quantity: 4,314 units. The detailed description of the subject of procurement, as well as the planned quantities, is included in the itemized price list provided as part of the public procurement documents. The contracting authority evaluates the offers based on the criterion of the lowest price, considering the specific rules for the procurement of medicines and medical devices specified in Section 6(3) of Government Decree 16/2012. Main financing conditions: The contracting authority will pay the value of the verified delivered call-offs later, within 30 days of receiving the invoice, via bank transfer, in accordance with Sections 135(1), (5)-(6) and (10) of the Public Procurement Act, considering the provisions of Section 6:130(1)-(2) of the Civil Code. Form of financing: post-financing. Support intensity: 100%. In case of delayed payment by the client, the Contractor is entitled to claim late interest in accordance with Section 6:155 of the Civil Code and the claim for arrears debt recovery as per Section 3 of the Act IX of 2016 on the Collection Costs. Payment currency: HUF. The contracting authority draws the bidders' attention to the provisions of Section 136(1) of the Public Procurement Act regarding payments and the special termination reason stated in Section 143(3). The detailed conditions for financial performance and financing are included in the draft contract.
LOT-0004
EKR000658412025/4
Antibodies necessary for general protein work.
Lot 4: Antibodies necessary for general protein work (20 items), framework amount: net HUF 2,767,506. anti-mo CD81 anti-Mouse Alexa Fluor Plus 488 anti-Mouse Alexa Fluor Plus 555 anti-Rabbit Alexa Fluor Plus 555 anti-Rabbit Alexa Fluor Plus 647 BIN1 Monoclonal Antibody (3B6F10) Cardiac Troponin I Antibody MINPP1 Polyclonal Antibody Wheat Germ Agglutinin, Alexa Fluor 488 Conjugate MYH6 Polyclonal Antibody IRE1 alpha Polyclonal Antibody Cardiac Troponin C Polyclonal Antibody MYH7 Polyclonal Antibody Neutrophil elastase Polyclonal Antibody anti-mouse H2-M3, PE anti-mouse CCL21, unconjugated anti-mouse MFGE8 (Lactadherin), unconjugated Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 405 Donkey anti-Goat IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 350 Goat anti-rat IgG (H+L) Secondary Antibody, APC Planned quantity: 3,857 units. The detailed description of the subject of procurement, as well as the planned quantities, is included in the itemized price list provided as part of the public procurement documents. The contracting authority evaluates the offers based on the criterion of the lowest price, considering the specific rules for the procurement of medicines and medical devices specified in Section 6(3) of Government Decree 16/2012. Main financing conditions: The contracting authority will pay the value of the verified delivered call-offs later, within 30 days of receiving the invoice, via bank transfer, in accordance with Sections 135(1), (5)-(6) and (10) of the Public Procurement Act, considering the provisions of Section 6:130(1)-(2) of the Civil Code. Form of financing: post-financing. Support intensity: 100%. In case of delayed payment by the client, the Contractor is entitled to claim late interest in accordance with Section 6:155 of the Civil Code and the claim for arrears debt recovery as per Section 3 of the Act IX of 2016 on the Collection Costs. Payment currency: HUF. The contracting authority draws the bidders' attention to the provisions of Section 136(1) of the Public Procurement Act regarding payments and the special termination reason stated in Section 143(3). The detailed conditions for financial performance and financing are included in the draft contract.
LOT-0006
EKR000658412025/6
Antibodies used for flow cytometry and Western blot.
6. section: Antibodies used for flow cytometry and Western blot (7 items), budget: net 1,323,442 HUF. anti-mouse CD274 (PDL-1, B7-H1) Super Bright 600 anti-mouse CD178 (Fas Ligand), APC-eFluor 780 anti-mouse CD11c, Superbright 600 anti-mouse CD197 (CCR7), PE-Cyanine7 anti-mouse CD45RO unconjugated Connexin 43 polyclonal antibody anti-hu CD63, APC Planned quantity: 1050 units. The detailed description of the subject of the procurement as well as the planned quantities are included in the itemized price list which also contains the technical description provided as part of the procurement documents. The contracting authority evaluates the bids based on the lowest price selection criterion, taking into account the specific rules of public procurement of medicines and medical devices as stipulated in Government Regulation 16/2012 (II. 16.) § 6 (3). Main financing conditions: The contracting authority will pay for the verified completed calls retrospectively, as per Kbt. § 135 (1), (5)-(6) and (10), by bank transfer within 30 days following receipt of the invoice, taking into account the provisions of Civil Code § 6:130 (1)-(2). Financing type: post-financing. Support intensity: 100% In the event of delayed payment by the client, the contractor is entitled to claim late interest as per Civil Code § 6:155 and the late fee pursuant to Act IX of 2016 § 3 on collection costs. The payment currency: HUF. The contracting authority draws the bidders' attention to the contents of Kbt. § 136 (1) regarding the payments, and the special termination reason stated in § 143 (3). The detailed conditions of financial performance and financing are included in the draft contract.
LOT-0007
EKR000658412025/7
Specific kits used with Leprechaun type measuring equipment.
7. section: Specific kits used with Leprechaun type measuring devices (8 items), budget: net 16,957,570 HUF. Leprechaun Exosome Starter Kit Leprechaun Exosome Human Plasma Kit Leprechaun Exosome Mouse Tetraspanin Kit Leprechaun Exosome Human Tetraspanin Flex Kit Leprechaun Exosome Human Plasma Flex Kit Leprechaun Flex Conjugation Reagents Leprechaun Flex Kit Leprechaun Exosome Human Tetraspanin Kit Planned quantity: 34 units. The detailed description of the subject of the procurement, as well as the planned quantities, is included in the itemized price list which also contains the technical description provided as part of the procurement documents. The contracting authority evaluates the bids based on the lowest price selection criterion, taking into account the specific rules of public procurement of medicines and medical devices as stipulated in Government Regulation 16/2012 (II. 16.) § 6 (3). Main financing conditions: The contracting authority will pay for the verified completed calls retrospectively, as per Kbt. § 135 (1), (5)-(6) and (10), by bank transfer within 30 days following receipt of the invoice, taking into account the provisions of Civil Code § 6:130 (1)-(2). Financing type: post-financing. Support intensity: 100% In the event of delayed payment by the client, the contractor is entitled to claim late interest as per Civil Code § 6:155 and the late fee pursuant to Act IX of 2016 § 3 on collection costs. The payment currency: HUF. The contracting authority draws the bidders' attention to the contents of Kbt. § 136 (1) regarding the payments, and the special termination reason stated in § 143 (3). The detailed conditions of financial performance and financing are included in the draft contract.
LOT-0008
EKR000658412025/8
Specific kits used with Quanterix type measuring equipment.
8. section: Specific kits used with Quanterix type measuring devices (17 items), budget: 9,263,436 HUF. "CorPlex Cytokine Panel 1 (10-Plex)" CorPlex IL-1β CorPlex IL-4 CorPlex TNF-α CorPlex IL-2 Chemokine Panel 1 (4-plex) Simoa Endoglin Developer Kit Simoa rat IL-1β Developer Kit Simoa mouse IL-10 Developer Kit Simoa mouse TNFα Developer Kit Simoa mouse ICAM-1 Developer Kit Simoa Planar Array Homebrew Assay Starter kit Planar Array Homebrew Plate (1-spot) Simoa Planar Array Homebrew Tag SuperSignal Luminol SuperSignal Peroxide Simoa Planar Array Homebrew Diluent A Planned quantity: 26 units. The detailed description of the subject of the procurement, as well as the planned quantities, is included in the itemized price list which also contains the technical description provided as part of the procurement documents. The contracting authority evaluates the bids based on the lowest price selection criterion, taking into account the specific rules of public procurement of medicines and medical devices as stipulated in Government Regulation 16/2012 (II. 16.) § 6 (3). Main financing conditions: The contracting authority will pay for the verified completed calls retrospectively, as per Kbt. § 135 (1), (5)-(6) and (10), by bank transfer within 30 days following receipt of the invoice, taking into account the provisions of Civil Code § 6:130 (1)-(2). Financing type: post-financing. Support intensity: 100% In the event of delayed payment by the client, the contractor is entitled to claim late interest as per Civil Code § 6:155 and the late fee pursuant to Act IX of 2016 § 3 on collection costs. The payment currency: HUF. The contracting authority draws the bidders' attention to the contents of Kbt. § 136 (1) regarding the payments, and the special termination reason stated in § 143 (3). The detailed conditions of financial performance and financing are included in the draft contract.
LOT-0009
EKR000658412025/9
Antibodies required for stem cell work.
9. section: Antibodies required for stem cell work (11 items), budget: 1,044,715 HUF. anti-mouse CD47, PE-Cyanine7 anti-mouse CD200, eFluor 660 anti-mouse CD45, Pacific Blue anti-mouse CD4, APC-eFluor 780 anti-mouse CD8a, PeCY5.5 anti-mouse CD19, PeCY5.5 anti-mouse CD25, PE-Cyanine7 SERPIN B9 anti-mouse CD3, APC anti-mouse CD105-APC, monoclonal, FC tested anti-mo CD9, FITC Planned quantity: 1051 units. The detailed description of the subject of the procurement, as well as the planned quantities, is included in the itemized price list which also contains the technical description provided as part of the procurement documents. The contracting authority evaluates the bids based on the lowest price selection criterion, taking into account the specific rules of public procurement of medicines and medical devices as stipulated in Government Regulation 16/2012 (II. 16.) § 6 (3). Main financing conditions: The contracting authority will pay for the verified completed calls retrospectively, as per Kbt. § 135 (1), (5)-(6) and (10), by bank transfer within 30 days following receipt of the invoice, taking into account the provisions of Civil Code § 6:130 (1)-(2). Financing type: post-financing. Support intensity: 100% In the event of delayed payment by the client, the contractor is entitled to claim late interest as per Civil Code § 6:155 and the late fee pursuant to Act IX of 2016 § 3 on collection costs. The payment currency: HUF. The contracting authority draws the bidders' attention to the contents of Kbt. § 136 (1) regarding the payments, and the special termination reason stated in § 143 (3). The detailed conditions of financial performance and financing are included in the draft contract.